SHH and medulloblastoma: Last, in order to corroborate the translational potential of our findings, we assessed both monotherapies as well as their combination in human patient-derived xenograft organoids (PDXOs) [30] representing SHH- and Group3-subgroup medulloblastoma (Fig. 6g,h).